Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating (NASDAQ:FLGT)

Core Insights - Fulgent Genetics, Inc. (FLGT) stock is currently trading at its 52-week highs following a significant double-digit gain over the past month, attributed to strong Q3 performance released in early November [1] Financial Performance - The company reported impressive Q3 numbers, contributing to its recent stock price surge [1] Market Position - The stock's performance indicates a positive market sentiment and investor confidence in Fulgent Genetics' growth potential [1]